Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:HOTH NASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.80-3.1%$2.83$2.44▼$5.46$93.88M0.64144,988 shs88,844 shsHOTHHoth Therapeutics$0.64-3.4%$0.78$0.49▼$2.12$12.24M0.571.92 million shs265,061 shsSILOSilo Pharma$0.41+5.1%$0.41$0.22▼$1.01$6.67M0.653.33 million shs70,136 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-0.34%-2.36%+0.35%+2.48%+13.33%HOTHHoth Therapeutics+1.46%-4.05%+3.10%-34.72%-23.46%SILOSilo Pharma+0.95%-6.19%-1.50%+35.40%-52.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.80-3.1%$2.83$2.44▼$5.46$93.88M0.64144,988 shs88,844 shsHOTHHoth Therapeutics$0.64-3.4%$0.78$0.49▼$2.12$12.24M0.571.92 million shs265,061 shsSILOSilo Pharma$0.41+5.1%$0.41$0.22▼$1.01$6.67M0.653.33 million shs70,136 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-0.34%-2.36%+0.35%+2.48%+13.33%HOTHHoth Therapeutics+1.46%-4.05%+3.10%-34.72%-23.46%SILOSilo Pharma+0.95%-6.19%-1.50%+35.40%-52.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.25Hold$8.50203.57% UpsideHOTHHoth Therapeutics 2.00Hold$5.00677.60% UpsideSILOSilo Pharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest HOTH, ANIX, and SILO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026HOTHHoth Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/24/2026SILOSilo Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/31/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/25/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/4/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K447.07N/AN/A$0.42 per share6.67HOTHHoth TherapeuticsN/AN/AN/AN/A$0.40 per shareN/ASILOSilo Pharma$70K96.23N/AN/A$0.47 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)HOTHHoth Therapeutics-$12.47M-$0.90N/AN/AN/AN/A-139.84%-126.88%6/3/2026 (Estimated)SILOSilo Pharma-$4.23M-$0.54N/AN/AN/A-5,870.83%-83.53%-63.70%N/ALatest HOTH, ANIX, and SILO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AHOTHHoth Therapeutics-$0.1378N/AN/AN/AN/AN/A5/27/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A3/27/2026Q4 2025HOTHHoth Therapeutics-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/27/2026Q4 2025SILOSilo PharmaN/A$0.03N/AN/AN/A$0.02 million3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A12.1812.18HOTHHoth TherapeuticsN/A4.724.72SILOSilo PharmaN/A11.3711.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%HOTHHoth Therapeutics7.08%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%HOTHHoth Therapeutics6.92%SILOSilo Pharma2.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableHOTHHoth Therapeutics419.13 million17.80 millionNot OptionableSILOSilo Pharma216.27 million15.91 millionNot OptionableHOTH, ANIX, and SILO HeadlinesRecent News About These CompaniesSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain InjuryMay 7, 2026 | globenewswire.comSilo Pharma, Inc.: Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | finanznachrichten.deSilo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | markets.businessinsider.comSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 29, 2026 | globenewswire.comSilo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, QwikagentsApril 22, 2026 | globenewswire.comSilo Pharma, Inc.: Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon ...April 20, 2026 | finanznachrichten.deSilo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon PsychedelicsApril 20, 2026 | markets.businessinsider.comSilo Pharma (SILO) Stock Rockets Nearly 50% on European PTSD Patent Approval SignalApril 8, 2026 | blockonomi.comSilo Pharma Rallies After Securing Key Patent AllowanceApril 7, 2026 | benzinga.comStock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In FocusApril 7, 2026 | benzinga.comSilo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention TherapyApril 6, 2026 | globenewswire.comSilo Pharma's Strategic Path Forward After Fiscal 2025March 7, 2026 | aktiencheck.deASilo Pharma stock surges on $1M share buyback programFebruary 23, 2026 | in.investing.comSilo Pharma Announces Share Buyback ProgramFebruary 23, 2026 | globenewswire.comSilo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property PortfolioFebruary 18, 2026 | globenewswire.comSilo Pharma executes LOI with Allucent for Phase 1 development of SPC-15December 31, 2025 | msn.comSilo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15December 30, 2025 | globenewswire.comSilo Pharma receives extended Nasdaq compliance grace periodDecember 29, 2025 | msn.comSilo Pharma, Inc. Selects Allucent to Support IND Submission for PTSD Treatment SPC-15November 17, 2025 | quiverquant.comQSilo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSDNovember 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOTH, ANIX, and SILO Company DescriptionsAnixa Biosciences NASDAQ:ANIX$2.80 -0.09 (-3.11%) As of 02:34 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Hoth Therapeutics NASDAQ:HOTH$0.64 -0.02 (-3.44%) As of 02:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Silo Pharma NASDAQ:SILO$0.41 +0.02 (+5.08%) As of 02:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
